{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+1&page=45", "query": { "condition": "Phase 1", "page": 45 }, "page_size": 10 }, "pagination": { "page": 45, "page_size": 10, "total_count": 18620, "total_pages": 1862, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+1&page=46&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Phase+1&page=44&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-30T17:23:58.091Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00253474", "title": "PEG-Interferon Alfa-2b in Treating Young Patients With Plexiform Neurofibroma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasm of Uncertain Malignant Potential", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "PEG-interferon alfa-2a", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Institutes of Health Clinical Center (CC)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 36, "start_date": "2005-09", "completion_date": "2011-01", "has_results": false, "last_update_posted_date": "2012-03-29", "last_synced_at": "2026-10-30T17:23:58.091Z", "location_count": 4, "location_summary": "Washington D.C., District of Columbia • Chicago, Illinois • Bethesda, Maryland + 1 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00253474" }, { "nct_id": "NCT06546423", "title": "Study of the Infectivity, Safety and Immunogenicity of Two Recombinant, Live-Attenuated, B/HPIV3 Vectored Vaccines Expressing the Fusion Glycoprotein of HMPV Delivered by Nasal Spray to HPIV3-Seropositive Children 24 to <60 Months of Age", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Human Metapneumovirus", "Human Parainfluenza Virus Type 3" ], "interventions": [ { "name": "B/HPIV3/HMPV-PreF-A vaccine", "type": "BIOLOGICAL" }, { "name": "B/HPIV3/HMPV-F-B365 vaccine", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "24 Months", "maximum_age": "59 Months", "sex": "ALL", "summary": "24 Months to 59 Months" }, "enrollment_count": 24, "start_date": "2024-07-12", "completion_date": "2025-06-04", "has_results": true, "last_update_posted_date": "2026-09-18", "last_synced_at": "2026-10-30T17:23:58.091Z", "location_count": 4, "location_summary": "Baltimore, Maryland • Columbia, Maryland • Rochester, New York + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Columbia", "state": "Maryland" }, { "city": "Rochester", "state": "New York" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT06546423" }, { "nct_id": "NCT03376659", "title": "Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Colorectal Cancer", "Colorectal Adenocarcinoma", "Pancreatic Adenocarcinoma", "Metastatic Pancreatic Cancer" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "CV301", "type": "BIOLOGICAL" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Georgetown University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2018-08-08", "completion_date": "2023-08-01", "has_results": true, "last_update_posted_date": "2024-02-05", "last_synced_at": "2026-10-30T17:23:58.091Z", "location_count": 1, "location_summary": "Washington D.C., District of Columbia", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03376659" }, { "nct_id": "NCT06088888", "title": "TGRX-678 US Phase I for Chronic Myelogenous Leukemia Patients", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Myelogenous Leukemia" ], "interventions": [ { "name": "TGRX-678", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Shenzhen TargetRx Co., Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2024-07-02", "completion_date": "2028-02-29", "has_results": false, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-10-30T17:23:58.091Z", "location_count": 2, "location_summary": "Houston, Texas • Seattle, Washington", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT06088888" }, { "nct_id": "NCT03831503", "title": "A Study of INO-A002 in Healthy Dengue Virus-naive Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "INO-A002", "type": "BIOLOGICAL" }, { "name": "CELLECTRA® 2000", "type": "DEVICE" }, { "name": "Dengue Fever Antibodies (IgG)", "type": "DEVICE" } ], "intervention_types": [ "BIOLOGICAL", "DEVICE" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 30, "start_date": "2019-02-07", "completion_date": "2022-10-03", "has_results": false, "last_update_posted_date": "2023-12-14", "last_synced_at": "2026-10-30T17:23:58.091Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03831503" }, { "nct_id": "NCT00799461", "title": "Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Atypical Chronic Myeloid Leukemia, BCR-ABL Negative", "Blastic Phase Chronic Myelogenous Leukemia", "Cancer Survivor", "Chronic Eosinophilic Leukemia", "Chronic Myelomonocytic Leukemia", "Chronic Neutrophilic Leukemia", "Chronic Phase Chronic Myelogenous Leukemia", "de Novo Myelodysplastic Syndromes", "Depression", "Disseminated Neuroblastoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Fatigue", "Long-term Effects Secondary to Cancer Therapy in Adults", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Nodal Marginal Zone B-cell Lymphoma", "Noncontiguous Stage II Adult Burkitt Lymphoma", "Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma", "Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma", "Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma", "Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma", "Noncontiguous Stage II Adult Lymphoblastic Lymphoma", "Noncontiguous Stage II Grade 1 Follicular Lymphoma", "Noncontiguous Stage II Grade 2 Follicular Lymphoma", "Noncontiguous Stage II Grade 3 Follicular Lymphoma", "Noncontiguous Stage II Mantle Cell Lymphoma", "Noncontiguous Stage II Marginal Zone Lymphoma", "Noncontiguous Stage II Small Lymphocytic Lymphoma", "Previously Treated Myelodysplastic Syndromes", "Primary Myelofibrosis", "Psychosocial Effects of Cancer and Its Treatment", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Refractory Multiple Myeloma", "Relapsing Chronic Myelogenous Leukemia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes", "Splenic Marginal Zone Lymphoma", "Stage I Multiple Myeloma", "Stage II Multiple Myeloma", "Stage III Adult Burkitt Lymphoma", "Stage III Adult Diffuse Large Cell Lymphoma", "Stage III Adult Diffuse Mixed Cell Lymphoma", "Stage III Adult Diffuse Small Cleaved Cell Lymphoma", "Stage III Adult Hodgkin Lymphoma", "Stage III Adult Immunoblastic Large Cell Lymphoma", "Stage III Adult Lymphoblastic Lymphoma", "Stage III Chronic Lymphocytic Leukemia", "Stage III Grade 1 Follicular Lymphoma", "Stage III Grade 2 Follicular Lymphoma", "Stage III Grade 3 Follicular Lymphoma", "Stage III Mantle Cell Lymphoma", "Stage III Marginal Zone Lymphoma", "Stage III Multiple Myeloma", "Stage III Small Lymphocytic Lymphoma", "Stage IV Adult Burkitt Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma", "Stage IV Adult Diffuse Mixed Cell Lymphoma", "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma", "Stage IV Adult Hodgkin Lymphoma", "Stage IV Adult Immunoblastic Large Cell Lymphoma", "Stage IV Adult Lymphoblastic Lymphoma", "Stage IV Chronic Lymphocytic Leukemia", "Stage IV Grade 1 Follicular Lymphoma", "Stage IV Grade 2 Follicular Lymphoma", "Stage IV Grade 3 Follicular Lymphoma", "Stage IV Mantle Cell Lymphoma", "Stage IV Marginal Zone Lymphoma", "Stage IV Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "internet-based intervention", "type": "OTHER" }, { "name": "questionnaire administration", "type": "OTHER" }, { "name": "psychosocial assessment and care", "type": "PROCEDURE" }, { "name": "assessment of therapy complications", "type": "PROCEDURE" }, { "name": "management of therapy complications", "type": "PROCEDURE" }, { "name": "fatigue assessment and management", "type": "PROCEDURE" }, { "name": "counseling intervention", "type": "OTHER" } ], "intervention_types": [ "OTHER", "PROCEDURE" ], "sponsor": "Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1337, "start_date": "2008-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2012-03-07", "last_synced_at": "2026-10-30T17:23:58.091Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00799461" }, { "nct_id": "NCT00731861", "title": "Phase I, Pharmacokinetic, Pharmacodynamic Trial of PTK787 and Paclitaxel in Combination for Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasm Metastasis", "Carcinoma" ], "interventions": [ { "name": "Paclitaxel plus PTK787", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Indiana University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2005-05", "completion_date": "2010-08", "has_results": false, "last_update_posted_date": "2014-09-11", "last_synced_at": "2026-10-30T17:23:58.091Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00731861" }, { "nct_id": "NCT01281150", "title": "Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Solid Neoplasm", "Estrogen Receptor Negative", "Estrogen Receptor Positive", "HER2/Neu Negative", "Male Breast Carcinoma", "Progesterone Receptor Negative", "Recurrent Breast Carcinoma", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Veliparib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2011-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-05-25", "last_synced_at": "2026-10-30T17:23:58.091Z", "location_count": 3, "location_summary": "Hershey, Pennsylvania • Pittsburgh, Pennsylvania", "locations": [ { "city": "Hershey", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01281150" }, { "nct_id": "NCT06136650", "title": "A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer (mCRPC)", "Prostatic Neoplasms" ], "interventions": [ { "name": "Opevesostat", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Fludrocortisone acetate", "type": "DRUG" }, { "name": "Hydrocortisone", "type": "DRUG" }, { "name": "Abiraterone acetate", "type": "DRUG" }, { "name": "Prednisone acetate", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1314, "start_date": "2023-12-18", "completion_date": "2030-12-02", "has_results": false, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-10-30T17:23:58.091Z", "location_count": 63, "location_summary": "Tucson, Arizona • Irvine, California • Los Angeles, California + 56 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Irvine", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06136650" }, { "nct_id": "NCT07776782", "title": "A Single-Dose Study of MT-201 and Concomitant Infliximab in Healthy Participants", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer" ], "interventions": [ { "name": "MT-201", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mirador Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "19 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "19 Years to 55 Years" }, "enrollment_count": 25, "start_date": "2026-07-16", "completion_date": "2026-11-12", "has_results": false, "last_update_posted_date": "2026-08-21", "last_synced_at": "2026-10-30T17:23:58.091Z", "location_count": 1, "location_summary": "San Diego, California", "locations": [ { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07776782" } ] }